542 related articles for article (PubMed ID: 19318394)
1. DNase 1 activity in patients with systemic lupus erythematosus: relationship with epidemiological, clinical, immunological and therapeutical features.
Martinez-Valle F; Balada E; Ordi-Ros J; Bujan-Rivas S; Sellas-Fernandez A; Vilardell-Tarres M
Lupus; 2009 Apr; 18(5):418-23. PubMed ID: 19318394
[TBL] [Abstract][Full Text] [Related]
2. Concentration of antibodies to extractable nuclear antigens and disease activity in systemic lupus erythematosus.
Agarwal S; Harper J; Kiely PD
Lupus; 2009 Apr; 18(5):407-12. PubMed ID: 19318392
[TBL] [Abstract][Full Text] [Related]
3. Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker.
Simón JA; Cabiedes J; Ortiz E; Alcocer-Varela J; Sánchez-Guerrero J
Rheumatology (Oxford); 2004 Feb; 43(2):220-4. PubMed ID: 13130152
[TBL] [Abstract][Full Text] [Related]
4. Hyperprolactinemia in males with systemic lupus erythematosus.
Mok CC; Lau CS; Lee KW; Wong RW
J Rheumatol; 1998 Dec; 25(12):2357-63. PubMed ID: 9858430
[TBL] [Abstract][Full Text] [Related]
5. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
[TBL] [Abstract][Full Text] [Related]
6. Anti-nucleosome and anti-chromatin antibodies are present in active systemic lupus erythematosus but not in the cutaneous form of the disease.
Souza A; da Silva LM; Oliveira FR; Roselino AM; Louzada-Junior P
Lupus; 2009 Mar; 18(3):223-9. PubMed ID: 19213860
[TBL] [Abstract][Full Text] [Related]
7. Clinical and immunological manifestations of systemic lupus erythematosus: study on 146 south Tunisian patients.
Jallouli M; Frigui M; Hmida MB; Marzouk S; Kaddour N; Bahloul Z
Saudi J Kidney Dis Transpl; 2008 Nov; 19(6):1001-8. PubMed ID: 18974596
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus.
Husebye ES; Sthoeger ZM; Dayan M; Zinger H; Elbirt D; Levite M; Mozes E
Ann Rheum Dis; 2005 Aug; 64(8):1210-3. PubMed ID: 15708887
[TBL] [Abstract][Full Text] [Related]
9. The effect of menopause on disease activity in systemic lupus erythematosus.
Urowitz MB; Ibañez D; Jerome D; Gladman DD
J Rheumatol; 2006 Nov; 33(11):2192-8. PubMed ID: 16981295
[TBL] [Abstract][Full Text] [Related]
10. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations.
Magalhães MB; da Silva LM; Voltarelli JC; Donadi EA; Louzada-Junior P
Scand J Rheumatol; 2007; 36(6):442-7. PubMed ID: 18092265
[TBL] [Abstract][Full Text] [Related]
11. Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis.
Becker-Merok A; Kalaaji M; Haugbro K; Nikolaisen C; Nilsen K; Rekvig OP; Nossent JC
Arthritis Res Ther; 2006; 8(6):R162. PubMed ID: 17062137
[TBL] [Abstract][Full Text] [Related]
12. Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity.
Zandman-Goddard G; Blank M; Langevitz P; Slutsky L; Pras M; Levy Y; Shovman O; Witte T; Doria A; Rovensky J; Shoenfeld Y
Ann Rheum Dis; 2005 Dec; 64(12):1698-702. PubMed ID: 16014675
[TBL] [Abstract][Full Text] [Related]
13. Autonomic dysfunction in patients with systemic lupus erythematosus.
Gamez-Nava JI; Gonzalez-Lopez L; Ramos-Remus C; Fonseca-Gomez MM; Cardona-Muñoz EG; Suarez-Almazor ME
J Rheumatol; 1998 Jun; 25(6):1092-6. PubMed ID: 9632069
[TBL] [Abstract][Full Text] [Related]
14. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations.
Vilá LM; Alarcón GS; McGwin G; Friedman AW; Baethge BA; Bastian HM; Fessler BJ; Reveille JD;
Rheumatology (Oxford); 2004 Mar; 43(3):358-63. PubMed ID: 14623949
[TBL] [Abstract][Full Text] [Related]
15. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort.
Mikdashi J; Handwerger B
Rheumatology (Oxford); 2004 Dec; 43(12):1555-60. PubMed ID: 15342927
[TBL] [Abstract][Full Text] [Related]
16. Features of systemic lupus erythematosus in Dnase1-deficient mice.
Napirei M; Karsunky H; Zevnik B; Stephan H; Mannherz HG; Möröy T
Nat Genet; 2000 Jun; 25(2):177-81. PubMed ID: 10835632
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
Morel J; Roubille C; Planelles L; Rocha C; Fernandez L; Lukas C; Hahne M; Combe B
Ann Rheum Dis; 2009 Jun; 68(6):997-1002. PubMed ID: 18676986
[TBL] [Abstract][Full Text] [Related]
18. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus?
To CH; Petri M
Arthritis Rheum; 2005 Dec; 52(12):4003-10. PubMed ID: 16320348
[TBL] [Abstract][Full Text] [Related]
19. Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual.
Vilá LM; Alarcón GS; McGwin G; Bastian HM; Fessler BJ; Reveille JD;
Arthritis Rheum; 2006 Oct; 55(5):799-806. PubMed ID: 17013840
[TBL] [Abstract][Full Text] [Related]
20. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases.
Braun A; Sis J; Max R; Mueller K; Fiehn C; Zeier M; Andrassy K
Scand J Rheumatol; 2007; 36(4):291-8. PubMed ID: 17763207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
